| 2024-11-20 | +2.83 % |
|
| 2024-11-19 | +0.43 % |
|
| 2024-11-18 | -1.71 % |
|
| 2024-11-15 | -4.16 % |
|
| 2024-11-13 | +0.87 % |
|
| 2024-11-12 | -7.14 % |
|
| 2024-11-11 | -1.07 % |
|
| 2024-11-08 | +1.05 % |
|
| 2024-11-06 | +0.78 % |
|
| 2024-11-05 | +0.75 % |
|
| 2024-11-04 | -0.72 % |
|
| 2024-10-30 | -0.15 % |
|
| 2024-10-29 | -0.37 % |
|
| 2024-10-28 | +0.06 % |
|
| 2024-10-25 | +0.41 % |
|
| 2024-10-24 | +0.25 % |
|
| 2024-10-23 | -1.49 % |
|
| 2024-10-22 | +0.92 % |
|
| 2024-10-21 | -1.53 % |
|
| 2024-10-18 | +0.1 % |
|
| 2024-10-16 | -1.06 % |
|
| 2024-10-15 | +0.14 % |
|
| 2024-10-14 | -1.14 % |
|
| 2024-10-11 | +2.29 % |
- Amgen (AMGN) stock rose by 2.29% amid mixed trading on major stock indexes, with analysts viewing it positively as the company is building a flat base that indicates potential growth, and investor sentiment remains strong amidst fluctuating market conditions influenced by recent inflation data and corporate earnings reports.
- Amgen (AMGN) stock rose 2.29% due to positive adjustments in hedge fund positions, favorable research ratings from analysts, and strong revenue growth reported in its recent quarterly earnings.
- Amgen (AMGN) stock increased by 2.29% due to institutional investors, such as Steigerwald Gordon & Koch Inc. and Vanguard Group, buying more shares, reflecting growing confidence in the company's performance and positive analyst ratings despite slightly missing earnings estimates.
- Amgen (AMGN) stock increased by 2.29% due to increased investments from various hedge funds and positive analyst ratings, indicating growing confidence in the company's performance and potential.
- Amgen (AMGN) stock rose 2.29% following GEM Asset Management LLC's increase in its stake by 14.2%, suggesting growing investor confidence and interest in the company's shares, alongside other hedge funds also raising their holdings in the stock.
- Amgen (AMGN) stock rose 2.29% last night, likely fueled by increased institutional investment, positive earnings performance despite a miss on EPS, and analysts' favorable ratings and price target adjustments.
|
| 2024-10-10 | -0.43 % |
- Amgen (AMGN) stock decreased by 0.43% following news that Alvotech's Marketing Authorization Application for a biosimilar to its drugs Prolia and Xgeva was accepted by the European Medicines Agency, indicating potential competition and reduced market exclusivity for Amgen's products.
- Amgen (AMGN) stock fell by 0.43% to $322.08, partly due to mixed earnings results that missed analyst expectations and concerns raised by brokerages regarding the stock's valuation, with warnings from some analysts about potential underperformance.
- The article primarily discusses Alvotech's acceptance of a Marketing Authorization Application by the European Medicines Agency for its biosimilar candidate AVT03, which could impact Amgen's products Prolia and Xgeva, leading to a -0.43% decrease in Amgen's stock price due to increased competition in the biosimilar market that may affect its revenue.
- Amgen (AMGN) stock dropped by 0.43% following the recent acquisition of shares by USA Financial Formulas, indicating ongoing market fluctuations and possibly investor reactions to hedge fund activities.
- The article discusses the tensions between activist investor Starboard Value and Pfizer, highlighting criticisms against CEO Albert Bourla regarding stock performance and acquisition strategies, ultimately framing them as misleading given the pharmaceutical industry's current landscape. Amgen (AMGN) stock may have declined by -0.43% due to broader market sentiments affecting pharmaceutical companies, especially in light of Pfizer's struggles, which reflect investor caution towards the sector as a whole.
|
| 2024-10-09 | +1.49 % |
- Amgen (AMGN) stock rose 1.49% following a report that Talbot Financial LLC increased its holdings in the company by 4.2% in the third quarter, indicating positive investor sentiment and confidence in Amgen's performance.
- Amgen (AMGN) stock rose 1.49% due to increased institutional investment, with several firms significantly boosting their positions in the company during the third quarter, indicating strong confidence in its future performance.
- Amgen (AMGN) stock rose 1.49% as several institutional investors, including Strategic Wealth Partners Ltd. and Vanguard Group Inc., increased their holdings in the company, indicating strong investor confidence and interest in Amgen's performance.
- Amgen (AMGN) stock rose by 1.49% following significant institutional investment increases and positive analyst ratings, indicating strong investor confidence and interest in the company's growth potential.
- Amgen (AMGN) stock gained 1.49% as institutional investors, including Daymark Wealth Partners LLC and others, increased their holdings, indicating confidence in the company’s prospects, alongside positive adjustments in analyst ratings and price targets.
|
| 2024-10-08 | +0.07 % |
|
| 2024-10-07 | -0.69 % |
|
| 2024-10-04 | +0.69 % |
|
| 2024-10-03 | -0.7 % |
|
| 2024-10-02 | -0.18 % |
|
| 2024-09-30 | -0.14 % |
|
| 2024-09-27 | +1.12 % |
|
| 2024-09-26 | +1.99 % |
- The article highlights the rise of Amgen (AMGN) stock by 1.99% amid a positive market trend, partly driven by the enthusiasm surrounding BioAge Labs' successful IPO and its collaboration with Eli Lilly on obesity treatments, which reflects investor optimism in the biotech sector.
Amgen's stock likely increased due to favorable market trends, boosted investor confidence in biopharmaceutical collaborations, and positive developments from companies like BioAge Labs.
- Amgen (AMGN) stock rose by 1.99% despite Toronto Dominion Bank reducing its holdings in the company, indicating a potential positive investor sentiment or other favorable market factors contributing to the stock's increase.
- Amgen's stock (AMGN) rose by 1.99% following the restatement of its "outperform" rating by Royal Bank of Canada, which set a price target of $362.00 for the company.
- Amgen (AMGN) stock rose 1.99% as investors recognized its strong position in the rare disease market, boosted by a significant acquisition and accelerating product sales, amidst a favorable monetary environment created by the Federal Reserve's policies.
- Amgen (AMGN) stock rose by 1.99% amid positive sentiment in the market following Pfizer's decision to withdraw its sickle cell drug, Oxbryta, after patient deaths, leading investors to pivot towards other companies working on sickle cell treatments, which benefited from the news.
|
| 2024-09-25 | -5.46 % |
- Amgen (AMGN) stock declined by 5.5% due to concerns that the results from its Phase 3 clinical trial for an eczema treatment, while meeting its primary endpoint, may not be strong enough to compete effectively in a market dominated by the existing medication Dupixent, developed by rivals Sanofi and Regeneron.
- Amgen (AMGN) stock dropped by 5.46% following an investor update that revealed Phase 3 trial data for its drug rocatinlimab, which, while outperforming placebo for atopic dermatitis, fell short of expectations compared to competitors, prompting concerns about market competitiveness.
- Amgen's stock (NASDAQ:AMGN) dropped 5.46% following the reissuance of an "underperform" rating by Robert W. Baird, which also set a $215.00 price target for the company.
- Amgen Inc. (NASDAQ:AMGN) shares dropped 4.6% on Wednesday, trading at $315.79, amid significantly lower trading volume and possibly influenced by broader market trends or company-specific news.
The decline in Amgen's stock price may be attributed to negative market sentiment or news affecting the biotech sector, which is common during periods of investor uncertainty.
- Amgen (AMGN) stock fell by 5.46% primarily due to fluctuations in market sentiment and investor behavior, despite a significant increase in holdings by the Public Sector Pension Investment Board.
|
| 2024-09-24 | -1.4 % |
|
| 2024-09-23 | -0.52 % |
|
| 2024-09-18 | +0.04 % |
|
| 2024-09-17 | -0.73 % |
|
| 2024-09-11 | +0.32 % |
|
| 2024-09-09 | +1.67 % |
|
| 2024-09-06 | -1.17 % |
|
| 2024-09-04 | +0.04 % |
|
| 2024-09-03 | -0.99 % |
|
| 2024-08-30 | +0.85 % |
|
| 2024-08-15 | +0.82 % |
|
| 2024-08-12 | -0.77 % |
|
| 2024-08-09 | -0.68 % |
|
| 2024-08-08 | +3.9 % |
|
| 2024-08-07 | -5 % |
|
| 2024-08-06 | +1.15 % |
|
| 2024-08-05 | -2.63 % |
|
| 2024-08-02 | -0.46 % |
|
| 2024-07-25 | -0.39 % |
|
| 2024-07-23 | -0.81 % |
|
| 2024-07-22 | +1.41 % |
|
| 2024-07-03 | -0.45 % |
|
| 2024-06-24 | +3.24 % |
|
| 2024-06-14 | +0.04 % |
|
| 2024-06-11 | -1.32 % |
|
| 2024-06-07 | -0.22 % |
|
| 2024-05-29 | -1.27 % |
|
| 2024-05-23 | -0.94 % |
|
| 2024-05-22 | -1.73 % |
|
| 2024-05-21 | +0.1 % |
- The article reports that the stock of Amgen (AMGN) went up by 0.1% last night, attributing this increase to factors such as positive market sentiment, favorable company news, or general industry trends.
- The article discusses Alvotech's recent financial results and corporate highlights, indicating a surge in revenue guidance and positive clinical trial results, leading to Amgen's (AMGN) stock increase due to their subsidiary, Alvotech's success in securing FDA approvals, signing strategic partnerships, and making progress in pipeline development for biosimilar medicines.
- The article discusses a licensing agreement between Alvotech and Dr. Reddy's for the commercialization of AVT03, Alvotech's biosimilar candidate to Prolia and Xgeva, leading to a 0.1% increase in Amgen (AMGN) stock due to the potential market expansion and increased access to biosimilar medications for patients.
- Last night, Amgen (AMGN) stock was up by 0.1%, and the stock price increase may be attributed to the news of a collaboration between Alvotech and Dr. Reddy's Laboratories for the commercialization of AVT03, Alvotech’s biosimilar candidate to Prolia® and Xgeva® (denosumab) which has the potential to offer cost-effective and critical biologic medications to patients globally.
|
